New cancer clinical trial: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

Published on: January 30, 2018 at 12:00PM
Condition:   Colorectal Cancer
Interventions:   Biological: Nivolumab;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: Fluorouracil;   Drug: Bevacizumab
Sponsors:   Bristol-Myers Squibb;   ONO Pharmaceutical Co.
Not yet recruiting
http://ift.tt/2no0W3V